According to Alzheimer’s Disease International, clinical trials for Alzheimer’s disease treatments face a global shortage of participants, risking slowing progress in dementia therapies. To sustain active clinical pipelines amid high screening rejection rates, an estimated 350,000 applicants are needed worldwide.
Global Alzheimer’s Clinical Trials Pipeline and Participant Shortfall
The global federation of Alzheimer associations released a report to mark World Alzheimer’s Day detailing the current scope of research. According to the report, 158 potential dementia therapies are currently being evaluated across 192 clinical trials worldwide.
Recent years have brought a wave of optimism with the arrival of disease-modifying drugs like lecanemab and donanemab. Unlike older medications that merely manage or mask symptoms, these newer treatments are engineered to slow the progression of the neurodegenerative disease. The report noted that the field is changing with remarkable speed, highlighting accelerating computational drug discovery, emerging blood tests, and a broader, more sophisticated drug pipeline than at any point in history.
Barriers to Clinical Trial Recruitment
Despite the expanding pipeline, recruitment remains a primary bottleneck. According to Alzheimer’s Disease International, multiple factors hamper public participation, including limited awareness of active trial opportunities and widespread misunderstandings about medical research.
In Japan, these recruitment hurdles are compounded by cultural and educational gaps. Noriyo Washizu, a nurse and member of Alzheimer’s Association Japan—a group consisting of people with dementia, care providers, and healthcare professionals—stated that the public generally lacks an understanding of how drugs are developed and approved.
“Clinical trials are often perceived as a special arrangement involving special people,” Washizu said. She pointed out that many individuals taking daily medications for conditions like blood pressure or osteoporosis do not realize a rigorous testing process sits behind those treatments.
Cultural Factors Impacting Medical Decisions in Japan
Medical industry culture in Japan also plays a role in suppressing trial enrollment. Washizu explained that a paternalistic culture remains pervasive, which frequently leaves patients without adequate support to make informed decisions regarding their own health.
This dynamic fosters an underlying aversion to voluntary clinical trial participation. To combat this reluctance, Washizu emphasized that information regarding clinical trials must be easy to access, fair, and grounded strictly in scientific evidence.
“Information should come not only from pharmaceutical companies, but also from governments and research institutions,” Washizu said. “People need to be able to access this information easily and make their own informed decisions.”
Did you know?
An estimated 350,000 applicants must step forward to account for high rates of people rejected in the screening process and keep current global Alzheimer’s clinical trials active.
Frequently Asked Questions
Why are participants needed for Alzheimer’s clinical trials?
According to Alzheimer’s Disease International, participant shortages threaten to slow progress on 158 potential dementia therapies currently tested across 192 global trials.
What are disease-modifying drugs?
Unlike traditional medications that only manage symptoms, disease-modifying drugs like lecanemab and donanemab are designed to slow the progression of Alzheimer’s disease.
How many people need to apply to clinical trials globally?
The global federation estimates that 350,000 people must apply to sustain active trials, factoring in high rates of people rejected in the screening process.
Take Action: Share this article to raise awareness about dementia research, or explore your local health authority’s portal to learn more about active clinical trials in your region.
Worth a look